Brexit Highlights Strong British Presence In EU Medicines Network
This article was originally published in SRA
Executive Summary
The decision by the UK to leave the EU has highlighted the important role the Medicines and Healthcare products Regulatory Agency plays in the European pharmaceutical regulatory network.
You may also be interested in...
UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’
Perhaps appealing to the wider European audience, UK legislators debating Brexit’s impact warn of damage to EU and as well as UK regulatory systems.
Settle Terms Before Brexit Divorce Is Final, Former EMA Chief Says
If the European Medicines Agency has to desert London as a result of the UK’s decision to leave the EU, it will have to take care in managing issues such as the loss of expert input from the UK regulator, the MHRA, says former EMA head Thomas Lönngren.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.